Efficacy and safety of twice-weekly teriparatide in hemodialysis patients with osteoporosis: protocol for a randomized controlled trial (START-HOP trial)
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at increased risk of bone fractures due to multifactorial skeletal fragility associated with CKD–mineral and bone disorder (CKD–MBD), secondary osteoporosis, and metabolic and nutritional abnormalities. Although secondary hyperparathyroidism (SHPT) can be managed using vitamin D analogs and calcimimetics, fracture risk often remains elevated despite appropriate CKD–MBD management, highlighting the need for therapies directly targeting skeletal fragility. Teriparatide, a synthetic human parathyroid hormone (PTH 1–34), has shown potential to improve bone mineral density (BMD) in patients with low PTH levels, although the evidence remains limited, particularly in dialysis populations. Notably, previous studies have employed once-weekly formulations, which have been associated with transient hypotension and a high rate of treatment discontinuation, thereby limiting the accumulation of robust evidence in this population. In contrast, the twice-weekly teriparatide autoinjector formulation may cause fewer adverse effects and would enhance treatment adherence. This improved tolerability could lead to better outcome of bone density maintenance over time. This trial aims to address the lack of evidence regarding teriparatide use in HD patients with adequately controlled SHPT. Methods The START-HOP trial is a multicenter, prospective, randomized, open-label, controlled trial designed to evaluate the efficacy and safety of twice-weekly teriparatide (28.2 μg) in HD patients with osteoporosis. A total of 50 participants will be enrolled and randomized (1:1) to either immediate initiation of teriparatide or a delayed-start group beginning treatment at week 48. The primary analysis will compare the percentage change in lumbar spine BMD at week 48 between groups in a randomized controlled trial (RCT) framework. In addition, within-group analyses will be conducted to assess changes before and after teriparatide administration in all participants over a 48-week treatment. Secondary endpoints include changes in femoral BMD, incidence of fractures, bone turnover markers, cardiovascular biomarkers, echocardiographic parameters, and adverse events. Between-group comparisons will be performed using unpaired t -tests, and within-group comparisons using paired t -tests. Conclusions The START-HOP trial will investigate the efficacy and safety of twice-weekly teriparatide in osteoporosis patients who undergo hemodialysis. Trial registration The study was registered with the Japan Registry of Clinical Trials (jRCTs011230047-2) on 13 November 2023.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy and safety of twice-weekly teriparatide in hemodialysis patients with osteoporosis: protocol for a randomized controlled trial (START-HOP trial)
- Date Crossref
- 22/04/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hokkaido University Institute of Health Science Innovation for Medical Care pays non établi dans la noticeUniversité ou école supérieure
-
NTT Medical Center pays non établi dans la noticeÉtablissement de santé
-
Hokushin General Hospital pays non établi dans la noticeÉtablissement de santé
-
Hokkaido hospital Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Hokkaido Orthopedic Surgery Memorial Hospital pays non établi dans la noticeÉtablissement de santé
-
Aishin Memorial Hospital pays non établi dans la noticeÉtablissement de santé
-
Miwa Hospital pays non établi dans la noticeÉtablissement de santé
-
Sapporo Science Center pays non établi dans la noticeInstitution
-
Kushiro Rosai Hospital pays non établi dans la noticeÉtablissement de santé
-
Sapporo Minami Hospital pays non établi dans la noticeÉtablissement de santé
-
Sapporo Kosei General Hospital pays non établi dans la noticeÉtablissement de santé
-
Hokkaido University Hospital pays non établi dans la noticeÉtablissement de santé
Institute of Health Science Innovation for Medical Care — Hokkaido University, NTT Medical Center et Hokushin General Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.